MedTrace Logo

Open Label, 4 Week Study of ITCA 650 in Adults With Type 2 Diabetes

NCT01798264 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 44

Last updated 2013-05-17

Study results available
· View outcomes & findings →

Summary

evaluate the safety and tolerability of ITCA 650 in subjects with type 2 diabetes mellitus.

Conditions

Interventions

DRUG

ITCA 650 (exenatide in DUROS)

Sponsors & Collaborators

  • Intarcia Therapeutics

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
30 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-02-28
Primary Completion
2009-05-31
Completion
2009-05-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01798264 on ClinicalTrials.gov